Dexin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dexin Xu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jian Ding
Department of Electrodiagnosis, Jilin Province FAW General Hospital, Changchun 130000, China
2 shared publications - Wenbin Zhang
Department of Cardiology, Jilin Province FAW General Hospital, Changchun, China
2 shared publications - Wenhai Wang
Department of Cardiology, Jilin Province FAW General Hospital, Changchun, China
2 shared publications Yinping Pan
Department of Pediatrics, Jilin Province FAW General Hospital, Changchun 130000, China
2 shared publicationsDuo Wang
Department of Geriatrics, Jilin Province FAW General Hospital, Changchun, 130000, People’s Republic of China
1 shared publication- Fang Wang
Department of Cardiology, Jilin Province FAW General Hospital, Changchun, China
1 shared publication
Latest Publications
- Open Access
- 3 May 2025
- Published by Elsevier in SLAS Technology
- Vol. 32, 100301
Contrast-enhanced ultrasonography combined with microbubbles for uterine disorders: Current trends and future perspectives
- 3 May 2025
- Published by Elsevier in SLAS Technology
- Vol. 32, 100301
Open AccessContrast-enhanced ultrasonography combined with microbubbles for uterine disorders: Current trends and future perspectives
- 9 April 2025
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (3) , 484-497
Nanotechnology Innovations in Myocardial Infarction: Diagnosis, Treatment and the Way Forward
Myocardial infarction (MI) is a global health concern that necessitates continued advancements in diagnostic and therapeutic modalities. Nanotechnology facilitates prompt diagnosis and personalized treatment. This manuscript explicitly reviews the application of innovative methodologies for identifying cardiac biomarkers to facilitate the early diagnosis of MI and its clinical management. Nanoscale agents such as nanoparticles and nanosensors have been employed for this purpose. Technological advancements in medical imaging are revolutionizing therapeutic approaches while reducing morbidity and mortality typically associated with cardiac tissue injury. Besides all, applications of nanotechnology in therapeutics have proven extremely effective. The development of nanoparticle-based customized drug delivery systems will contribute to more effective treatments, fewer side effects, and improved therapeutic outcomes. Biomaterials and nanoscale surgical technologies may benefit patients with MI by promoting tissue regeneration and repair. This manuscript also investigates the ethical and legal limitations that could prevent seamless incorporation of nanotechnology into clinical practice. Graphical Abstract
- 9 April 2025
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (3) , 484-497
Nanotechnology Innovations in Myocardial Infarction: Diagnosis, Treatment and the Way Forward
Myocardial infarction (MI) is a global health concern that necessitates continued advancements in diagnostic and therapeutic modalities. Nanotechnology facilitates prompt diagnosis and personalized treatment. This manuscript explicitly reviews the application of innovative methodologies for identifying cardiac biomarkers to facilitate the early diagnosis of MI and its clinical management. Nanoscale agents such as nanoparticles and nanosensors have been employed for this purpose. Technological advancements in medical imaging are revolutionizing therapeutic approaches while reducing morbidity and mortality typically associated with cardiac tissue injury. Besides all, applications of nanotechnology in therapeutics have proven extremely effective. The development of nanoparticle-based customized drug delivery systems will contribute to more effective treatments, fewer side effects, and improved therapeutic outcomes. Biomaterials and nanoscale surgical technologies may benefit patients with MI by promoting tissue regeneration and repair. This manuscript also investigates the ethical and legal limitations that could prevent seamless incorporation of nanotechnology into clinical practice. Graphical Abstract
- Open Access
- 10 July 2023
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 19, 581-597
Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis
Accumulation of aberrant proteins in the heart causes cardiac amyloidosis, an uncommon and complicated illness. It can be classified into two main types: light chain (AL) and transthyretin (ATTR). The diagnosis of cardiac amyloidosis is challenging due to its non-specific clinical presentation and lack of definitive diagnostic tests. Diagnostic accuracy has increased with the advent of modern imaging methods, including cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Depending on the severity of cardiac amyloidosis, a number of treatments may be attempted and specified according to the subtype of amyloidosis and the presence of complications. However, there are still significant challenges in treating this condition due to its complexity and lack of effective treatments. The prognosis for patients with cardiac amyloidosis is poor. Despite recent advances in diagnosis and treatment, there is still a need for more effective treatments to improve outcomes for patients with this condition. Therefore, we aim to review the current and future therapeutics reported in the literature and among ongoing clinical trials recruiting patients with CA.
- 10 July 2023
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 19, 581-597
Open AccessStatus and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis
Accumulation of aberrant proteins in the heart causes cardiac amyloidosis, an uncommon and complicated illness. It can be classified into two main types: light chain (AL) and transthyretin (ATTR). The diagnosis of cardiac amyloidosis is challenging due to its non-specific clinical presentation and lack of definitive diagnostic tests. Diagnostic accuracy has increased with the advent of modern imaging methods, including cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Depending on the severity of cardiac amyloidosis, a number of treatments may be attempted and specified according to the subtype of amyloidosis and the presence of complications. However, there are still significant challenges in treating this condition due to its complexity and lack of effective treatments. The prognosis for patients with cardiac amyloidosis is poor. Despite recent advances in diagnosis and treatment, there is still a need for more effective treatments to improve outcomes for patients with this condition. Therefore, we aim to review the current and future therapeutics reported in the literature and among ongoing clinical trials recruiting patients with CA.